

# ForPatients

by Roche

Wild Type Melanoma Skin Cancer

## A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

**Trial Status**  
Terminated

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT03273153 2016-004387-18  
CO39722

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03273153 2016-004387-18 CO39722**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---